MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Coxsackievirus B3 (CVB3) has potential as a new oncolytic agent for the treatment of cancer but can induce severe pancreatitis. Here, we inserted target sequences of the microRNA miR-375 (miR-375TS) into the 5′ terminus of the polyprotein encoding sequence or into the 3′UTR of the CVB3 strain rCVB3.1 to prevent viral replication in the pancreas. In pancreatic EndoC-βH1 cells expressing miR-375 endogenously, replication of the 5′-miR-375TS virus and that of the 3′-miR-375TS virus was reduced by 4 × 103-fold and 3.9 × 104-fold, respectively, compared to the parental rCVB3.1. In colorectal carcinoma cells, replication and cytotoxicity of both viruses were slightly reduced compared to rCVB3.1, but less pronounced for the 3′-miR-375TS virus. Thus, CVB3 with miR-375TS in the 3′UTR of the viral genome may be suitable to avoid pancreatic toxicity.
Details
Original language | English |
---|---|
Pages (from-to) | 763-775 |
Number of pages | 13 |
Journal | FEBS letters |
Volume | 594 |
Issue number | 4 |
Publication status | Published - 1 Feb 2020 |
Peer-reviewed | Yes |
External IDs
PubMed | 31643074 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- cancer therapy, colorectal cancer, coxsackievirus B3, microRNA, oncolytic virus